Interferon-alpha 2b (IFNα) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: Results of a randomized multicentre study

British Journal of Haematology

Volumn 94, Issue 2, 1996, Pages 362-369

  Langenmayer, Irmgard ^a   Nerl, Christoph ^b   Knauf, Wolfgang ^c   Dempster, Sarah ^a   Hallek, Michael ^a   Adorf, Dagmar ^b   Dietzfelbinger, Hermann ^d   Busch, Raymonde ^d   Ziegler Heitbrock, Hans Werner ^a   Thiel, Eckhard ^c   Emmerich, Bertold ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b I Medizinische Abteilung   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Binet stage; chronic lymphocytic leukaemia; disease progression; interferon alpha 2b; serum thymidine kinase

Indexed keywords

ALPHA2B INTERFERON; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; IMMUNOGLOBULIN G; PARACETAMOL; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON; THYMIDINE;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME; B CELL LEUKEMIA; BETA 2 MICROGLOBULIN URINE LEVEL; BONE MARROW; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CELL INFILTRATION; CLINICAL EFFECTIVENESS; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EXHAUSTION; FEVER; FLU LIKE SYNDROME; HEART DISEASE; HIGH RISK PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; LOW RISK PATIENT; LYMPHATIC LEUKEMIA; LYMPHOCYTE; NAUSEA; NIGHT SWEAT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 8944256086     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1796.x     Document Type: Article

References (51)

1. Aguilar-Santelises, M., Loftenius, A., Ljungh, C., Svenson, S.B., Andersson, B., Mellstedt, H. & Jondal, M. (1992) Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2 microglobulin in patients with B-CLL and benign B lymphocytosis. Leukemia Research, 16, 607-613.
2. Bartl, R., Frisch, B., Burkhardt, R., Hoffman-Fezer, G., Demmler, K. & Sund, N. (1982) Assessment of marrow trephine in relation to staging in chronic lymphocytic leukaemia. British Journal of Haematology, 51, 1-15.
3. Binet, J.L., Auquier, A., Dighiero, C.G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Thomas, M., Tchernia, G., Jacquillat, C., Boivin, P., Lesty, C., Duault, M.T. & Montconduit, M. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
4. Boussiotis, V.A. & Pangalis, G.A. (1988) Randomized clinical trial with alpha-2b Interferon in 26 stage-A untreated B-chronic lymphocytic leukemia patients. Nouvelle Revue Française d'Hématologie, 30, 471-473.
5. Boussiotis, V.A. & Pangalis, G.A. (1991) Interferon alfa-2b therapy in untreated early stage. B-chronic lyrnphocytic leukaemia patients: one-year follow-up. British Journal of Haematology, 79, (Suppl. 1), 30-35.
6. Catovsky, D., Fooks, J. & Richards, S. (1988) The UK Medical Research Council CLL trials 1 and 2. Nouvelle Revue Française d'Hématologie, 30, 423-427.
7. Catovsky, D., Fooks, J. & Richards, J. (1989) Prognostic factors in chronic lymphocytic leukaemia: the importance of sex, age and response to treatment in survival. British Journal of Haematology, 72, 141-149.
8. Cheson, B.D., Bennett, J.M., Rai, K.R., Grever, M.R., Kay, N.E., Schiffer, C.A., Oken, M.M., Keating, M.J., Boldt, D.H., Kempin, S.J. & Foon, K.A. (1988) Guidelines for Clinical Protocols for Chronic Lymphocytic Leukemia: Recommendations of the National Cancer Institute-Sponsored Working Group. American Journal of Hematology, 29, 152-163.
9. Christiansen, I., Gidlöf, C., Wallgren, A.C., Simonsson, B. & Töttermann, T.H. (1994) Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood, 84, 3010-3016.
10. 2 microglohulin in malignant lymphoproliferative disorders. Cancer, 55, 2584-2589.
11. Dahlke, E., Schlag, R., Langenmayer, I., Frankenberger, M., Käfferlein, K., Subkowski, T., Emmerich, B. & Ziegler-Heitbrock, H.W.L. (1995) Decreased production of TNF and IL-6 in whole blood of CLL patients. American Journal of Hematology, 49, 76-82.
12. Demeter, J., Paloczi, K., Bibok, G. & Lehoczky, D. (1992) Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-alpha 2B therapy. Leukemia, 6, (Suppl. 3), 41S-45S.
13. Di Giovanni, S., Valentini, G., Carducci, P. & Giallonardo, P. (1989) Beta-2-microglobulin is a reliable tumour marker in chronic lymphocytic leukaemia. Acta Haematologica, 81, 181-185.
14. Flieger, D., Emmerich, B., Meyer, N., Riethmüller, G. & Ziegler-Heitbrock, H.W.L. (1990) Deficient production of tumor necrosis factor by peripheral blood monocytes in chronic lymphocytic leukemia. International Journal of Cancer, 45, 280-286.
15. Foa, R., Massaia, M., Cardona, S., Gillio Tos, A., Bianchi, A., Attisano, C., Guarini, A., Di Cello, P.F. & Fierro, M.T. (1990) Production of tumour necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood, 76, 393-400.
16. Foon, K.A., Sherwin, S.A., Abrams, P.G., Longo, D.L. & Fer, M.F. (1984) Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte α-interferon. New England Journal of Medicine, 311, 1148-1152.
17. French Cooperative Group on Chronic Lymphocytic Leukemia (1990a) Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial in 612 patients. Blood, 75, 1414-1421.
18. French Cooperative Group on Chronic Lymphocytic Leukemia (1990b) Natural history of stage A chronic lymphocytic leukaemia untreated patients. British Journal of Haematology, 76, 45-57.
19. Gutterman, J.U. (1994) Cytokine therapeutics: lessons from interferon α. Proceedings of the National Academy of Sciences of the United States of America, 91, 1198-1205.
20. Hallek, M., Emmerich, B., Strohmeyer, S., Busch, R., Reichle, A. & Senekowitsch, R. (1988) Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors. Klinische Wochenschrift, 66, 718-723.
21. 2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leukemia and Lymphoma, in press.
22. Heslop, H.E., Bianchi, A.C.M., Cordingley, F.T., Turner, M., De Mel, C.P., Hoffbrand, A.V. & Brenner, M.K. (1990) Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. Journal of Experimental Medicine, 172, 1729-1734.
23. Horning, S.J., Mergian, T.C., Krown, S.E., Gutterman, M.D., Louie, A., Gallagher, J., McCravey, J., Abramson, M.D., Cabanillas, F., Oettgen, H. & Rosenberg, A. (1985) Human interferon alpha in malignant lymphoma and Hodgkin's disease. Cancer, 56, 1305-1310.
24. International Workshop on Chronic Lymphocytic Leukemia (IWCLL) (1989) Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. Annals of Internal Medicine, 110, 236-238.
25. Källander, C.F.R., Simonsson, B., Hagberg, H. & Gronowitz, J.S. (1984) Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer, 54, 2450-2455.
26. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
27. Knauf, W.U., Raghavachar, A., Zeigmeister, B., Ludwig, W.D. & Thiel, E. (1994) Serum levels of s CD8, s CD25 and s CD23 in B-cell chronic lymphocytic leukemia: corrrelation with disease activity and tumour load. Cytokines in Hemopoiesis, Oncology, Immunology III (ed. by M. Freund, H. Link, R. Schmidt and K. Welte), pp. 435-440, Springer, Berlin.
28. Marotta, G., Zagonel, V. & Pinto, A. (1993) Induction of LFA-1/CD lia and ICAM-1/CD 54 adhesion molecules on neoplastic B cells during in vivo treatment of chronic lymphocytic leukemia with interferon α2. Blood, 81, 267-269.
29. McSweeney, E.N., Giles, F.J., Worman, C.P., Jewel, A.P., Tsakona, C.P., Hofbrand, A.V., Mehta, A.B., Newland, A.C., Cawley, J.C., Galvani, D., Singer, C.R.J., Grant, I.R., Norfolk, D.R. & Goldstone, A.H. (1993) Recombinant interferon alpha 2a in the treatment of patients with early-stage B chronic lymphocytic leukaemia. British Journal of Haematology, 85, 77-83.
30. Molica, S. (1991) Progression and survival studies in early chronic lymphocytic leukemia. Blood, 78, 895-899.
31. Molica, S. & Alberti, A. (1987) Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia. Cancer, 60, 2712-2716.
32. Molica, S. & Alberti, A. (1990) Recombinant alpha-2a interferon in treatment of chronic lymphocytic leukaemia: a preliminary report with emphasis on previously untreated patients in early stage of disease. Haematologica (Pavia), 75, 75-78.
33. Montserrat, E., Sanchez-Bisono, J., Vinolas, N. & Rozman, C. (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. British Journal of Haematology, 62, 567-575.
34. Montserrat, E., Vinolas, N., Reverter, J.C. & Rozman, C. (1988) Natural history of chronic lymphocytic leukaemia: on the progression and prognosis of early clinical stages. Nouvelle Revue Française d'Hématologie, 30, 359-361.
35. Morabito, F., Callea, V., Oliva, B., Stelitano, C., Vincelli, I., Molica, S., Alberti, A., Brugatelli, M. & Nobile, F. (1993) Alpha2-interferon in B-cell chronic lymphocytic leukemia: clinical response, serum cytokine levels, and immunophenotype modulation. Leukemia, 7, 366-371.
36. O'Connell, M.J., Colgan, J.P., Oken, M.M., Ritts, R.I., Jr, Kay, N.I. & Itri, L.M. (1986) Clinical trial of recombinant leukocyte A interferon as initial therapy for favourable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia: an Eastern Cooperative Oncology Group pilot study. Journal of Clinical Oncology, 4, 128-136.
37. Östlund, L., Biberfeld, P., Robert, K.H., Christensson, B. & Einhorn, S. (1989) Induction of proliferation and blast transformation by Interferon in human malignant and non-malignant lymph node B cells. Blood, 73, 2171-2181.
38. Pangalis, G.A. & Griva, E. (1988) Recombinant alfa-2b-interferon therapy in untreated stages A and B chronic lymphocytic leukemia. Cancer, 61, 869-872.
39. Pangalis, G.A., Roussou, P.A., Kittas, C., Kokkinou, S. & Fessas, P. (1987) B-chronic lymphocytic leukemias: prognostic implication of bone marrow histology in 120 patients: experience from a single hematology unit. Cancer, 59, 767-771.
40. Prange, H.W. (1994) Interferon-alpha: zum Problem der persistierenden Neurotoxizität. Deutsches Ärzteblatt, 91(49 B), 2508-2513.
41. Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy R.N. & Pasternack, B.S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-234.
42. Reinisch, W., Willheim, M., Hilgarth, M., Gasche, C., Mader, R., Szepfalusi, S., Steger, G., Berger, R., Lechner, K., Boltz-Nitulescu, G. & Schwarzmeier, J.D. (1994) Soluble CD 23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. Journal of Clinical Oncology, 12, 2146-2152.
43. Robert, K.H., Einhorn, S., Östlund, L., Juliusson, G. & Biberfeld, P. (1986) Interferon induces proliferation in leukemic and normal B-cell subsets. Hematological Oncology, 4, 113-120.
44. Rozman, C., Montserrat, E., Rodriguez-Fernandez, J.M., Ayats, R., Vallespi, T., Parody, R., Rios, A., Prados, D., Morey, M., Gomis, F., Alcala, A., Guiterrez, M., Maldonado, J., Gonzalez, C., Giralt, M., Herandez-Nieto, L., Cabrera, A. & Fernandez-Rananda, J.M. (1984) Bone marrow histologic pattern: the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate analysis of 329 cases. Blood, 64, 642-648.
45. Rozman, C., Montserrat, E., Vinolas, N., Urbano-Ispizua, A., Ribera, J.M., Gallart, T. & Compernolle, C. (1988) Recombinant alpha-2 Interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood, 71, 1295-1298.
46. Sartori, M., Andorno, S., La Terra, G., Pozzoli, G., Rudoni, M., Sacchetti, G.M., Inglese, E. & Aglietta, M. (1995) Assessment of Interferon cardiotoxicity with quantitative radionuclide angiocardiography. European Journal of Clinical Investigation, 25, 68-70.
47. Schulof, R.S., Lloyd, M.J., Stallings, J.J., Mai, D., Phillips, T.M., Jones, G.J. & Schechter, G.P. (1985) Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. Journal of Biological Research Modifiers, 4, 310-323.
48. Shustik, C., Mick, R., Silver, R., Sawitsky, A., Rai, K.R. & Shapiro, L. (CALGB) (1988) Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematological Oncology, 6, 7-12.
49. Talpaz, M., Rosenblum, M., Kurzrock, R., Reuben, J., Kantarjian, H. & Gutterman, J. (1987) Clinical and laboratory changes induced by alfa Interferon in chronic lymphocytic leukemia: a pilot study. American Journal of Hematology, 24, 341-350.
50. Villamor, N., Reverter, J.C., Montserrat, E., Urbano-Ispizua, A., Vives-Corrons, J.L. & Rozman, C. (1992) Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia. Leukemia, 6, 547-552.
51. Ziegler-Heitbrock, H.W.L., Schlag, R., Flieger, D. & Thiel, E. (1989) Favorable response of early stage-B CLL patients to treatment with IFN-α2. Blood, 73, 1426-1430.